Phase 1 Myeloma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been confirmed with a diagnosis of multiple myeloma according to established international guidelines (IMWG criteria).
• People whose multiple myeloma is currently in a first complete response (full or stringent), or has partially responded or responded very well to treatment, as measured by IMWG guidelines.
• People whose treating doctor considers them a suitable candidate for a stem cell transplant using their own cells (autologous transplant) with a chemotherapy drug called melphalan.
• People aged 18 or older.
• People who are reasonably active and able to care for themselves, based on a standard medical fitness scale (ECOG score of 0, 1, or 2).
• People whose bone marrow and major organs (liver and kidneys) are functioning well enough to meet specific blood test thresholds set by the trial.
• People who are willing and able to use reliable contraception (hormonal, barrier, or abstinence) before joining the trial and for one year after transplant — this applies to both women who could become pregnant and men. Anyone who suspects a pregnancy has occurred during this time must inform their treating doctor immediately.
• People who are able to understand and are willing to sign an informed consent form approved by an ethics review board (or have a legal representative do so on their behalf).

Who may not be able to join:

• People who have taken high doses of corticosteroids (more than the equivalent of 5 mg of prednisone per day) within two weeks before the trial begins, except when used as part of a stem cell collection preparation (mobilization regimen).
• People with a history of T-cell blood cancer, plasma cell leukaemia, amyloidosis, or another cancer — unless it was a non-invasive skin cancer, a non-melanoma skin cancer, or a cancer for which all treatment was completed at least two years before the trial starts with no signs of the disease remaining.
• People who are currently taking part in another clinical trial involving an experimental treatment.
• People who have had a significant allergic reaction to drugs that are chemically or biologically similar to any of the treatments used in this trial, including CYT107 or melphalan.
• People who have taken certain immune-suppressing medications (azathioprine, methotrexate, or anti-TNF agents) within two weeks before the trial begins.
• People with a history of a congenital (inherited) immune deficiency condition, or an autoimmune disease — though people whose autoimmune condition is well controlled on a low dose of medication (5 mg prednisone equivalent or less per day) may still be considered.
• People with a history of significant lung problems, such as severe asthma, severe chronic obstructive pulmonary disease (COPD), restrictive lung disease, a blood clot in the lungs within the past three months, or any active or prior inflammatory lung condition.
• People with serious uncontrolled health conditions, including active infections, heart failure, unstable chest pain, or irregular heart rhythms.
• People who are pregnant or breastfeeding. Women who could become pregnant must have a negative pregnancy test within seven days before the trial begins.
• People who do not have a backup supply of their own stem cells available.

Important: Always verify eligibility with the trial site directly before applying.